South Korean biopharmaceutical company Celltrion announced on the 18th that it has received approval from the European Medicines Agency (EMA) to proceed with a global Phase 3 clinical trial for CT-P55, a biosimilar of Cosentyx (secukinumab). With this approval, Celltrion will initiate a global Phase 3 trial involving 375 patients with plaque psoriasis to assess the efficacy, safety, and equivale..

According to pharmaceutical market research firm IQVIA, Vegzelma achieved a 29% market share in Europe as of Q3 last year, surpassing all competing bevacizumab products, including the original drug. This milestone was reached just two years after its European launch in October 2022. In that quarter alone, Vegzelma's market share increased by 9 percentage points (9%P) compared to the previous qua..

Celltrion announced on the 23rd that it has completed the launch of its autoimmune disease treatment, Steqeyma (active ingredient: ustekinumab), in five major European countries: Germany, Spain, the United Kingdom, Italy, and France. On January 20 (local time), Celltrion introduced Steqeyma in France, one of Europe’s key markets. The French subsidiary of Celltrion is actively promoting the produ..